Page 134 - 《中国药房》2021年22期

性类风湿关节炎的疗效及安全性评估[J].中华疾病控制 data and long-term clinical trial data[J]. Rheumatol Ther，
杂志，2018，22（2）：211-214. 2020，7（1）：121-131.
[23] 徐辉，邓玲，李学荣.托珠单抗治疗活动性难治性类风湿 [34] KAEGI C，STEINER U C，WUEST B，et al. Systematic
关节炎的疗效及不良反应[J].中国医刊，2019，54（4）： review of safety and efficacy of belimumab in treating
425-427. immune-mediated disorders[J]. Allergy，2021，76（9）：
[24] 施卫民.托珠单抗对难治性类风湿关节炎患者血清 2673-2683.
TL1A、IL-17 的影响[J].现代实用医学，2018，30（12）： [35] ARJUN M N，HEGDE A，SHANMUGANANDAN K，
1619-1621. et al. Safety and efficacy of abatacept among patients with
[25] 黄煜鹏，刘钢.托珠单抗治疗难治性类风湿关节炎的疗效 refractory rheumatoid arthritis：experience from a north
与安全性[J].华西医学，2017，32（7）：988-992. Indian tertiary care hospital[J]. Indian J Rheumatol，2018，
[26] JEON H L，KIM S C，PARK S H，et al. The risk of serious 13（3）：163-167.
infection in rheumatoid arthritis patients receiving toci- [36] PASCART T，PHILIPPE P，DRUMEZ E，et al. Abatacept
lizumab compared with tumor necrosis factor inhibitors in monotherapy versus abatacept plus methotrexate for treat-
Korea[J]. Semin Arthritis Rheum，2021，51（5）：989-995. ment-refractory rheumatoid arthritis[J]. Am J Ther，2019，
[27] ALETAHA D，BINGHAM C O 3rd，TANAKA Y，et al. 26（3）：e358-e363.
Efficacy and safety of sirukumab in patients with active [37] 徐东，曾小峰.阿巴西普治疗类风湿关节炎的机制及临床
rheumatoid arthritis refractory to anti-TNF therapy 研究进展[J].中华风湿病学杂志，2020，24（10）：702-709.
（SIRROUND-T）：a randomised，double-blind，placebo- [38] 张舒，王其琼，胡咏川，等.选择性 JAK 抑制剂：巴瑞替
controlled，parallel-group，multinational，phase 3 study[J]. 尼[J].临床药物治疗杂志，2019，17（8）：5-8，22.
Lancet，2017，389（10075）：1206-1217. [39] 杨玉慧，许秀丽，张波.治疗类风湿性关节炎新药托法替
[28] TAKEUCHI T，YAMANAKA H，HARIGAI M，et al. Siru- 布[J].临床药物治疗杂志，2018，16（12）：53-56，60.
kumab in rheumatoid arthritis refractory to sulfasalazine [40] 陈春燕，周华俊，周宇一，等.托法替尼联合甲氨蝶呤在类
or methotrexate：a randomized phase 3 safety and efficacy 风湿性关节炎合并高危因素患者中的应用价值[J].现代
study in Japanese patients[J]. Arthritis Res Ther，2018，20 实用医学，2019，31（12）：1623-1625.
（1）：42. [41] EMERY P，BLANCO R，MALDONADO COCCO J，
[29] TANAKA Y，TAKEUCHI T，HARIGAI M，et al. Efficacy et al. Patient-reported outcomes from a phase Ⅲ study of
and safety of sirukumab in Japanese patients with active baricitinib in patients with conventional synthetic DMARD-
rheumatoid arthritis who were refractory or intolerant to refractory rheumatoid arthritis[J]. RMD Open，2017，3
anti-tumor necrosis factor therapy：subgroup analysis of a （1）：e000410.
randomized，double-blind，multicenter，phase 3 study [42] GENOVESE M C，KREMER J M，KARTMAN C E，et al.
（SIRROUND-T）[J]. Mod Rheumatol，2019，29（2）：306- Response to baricitinib based on prior biologic use in
313. patients with refractory rheumatoid arthritis[J]. Rheuma-
[30] SOYSAL E，ULUTAŞ F，TEPELI E，et al. IL-23R gene tology（Oxford），2018，57（5）：900-908.
polymorphisms in rheumatoid arthritis[J/OL]. Rheumatol [43] GENOVESE M C，KALUNIAN K，GOTTENBERG J E，
Inter，2021[2021-09-22]. https：//www.researchgate.net/ et al. Effect of filgotinib vs placebo on clinical response in
publication/351546100_IL-23R_gene_polymorphisms_in_ patients with moderate to severe rheumatoid arthritis
rheumatoid_arthritis. DOI：10.1007/s00296-021-04881-9. refractory to disease-modifying antirheumatic drug thera-
[31] KLIMIUK P A，DOMYSŁAWSKA I，SIERAKOWSKI S， py：the FINCH 2 randomized clinical trial[J]. JAMA，
et al. Regulation of serum matrix metalloproteinases and 2019，322（4）：315-325.
tissue inhibitor of metalloproteinases-1 following rituximab [44] GENOVESE M C，FLEISCHMANN R，COMBE B，et al.
therapy in patients with rheumatoid arthritis refractory to Safety and efficacy of upadacitinib in patients with active
anti-tumor necrosis factor blockers[J]. Rheumatol Int， rheumatoid arthritis refractory to biologic disease-modify-
2015，35（4）：749-755. ing anti-rheumatic drugs（SELECT-BEYOND）：a dou-
[32] TORRENTE-SEGARRA V，ACOSTA PEREIRAA，MORLA ble-blind，randomised controlled phase 3 trial[J]. Lancet，
R，et al.VARIAR study：assessment of short-term efficacy 2018，391（10139）：2513-2524.
and safety of rituximab compared to an anti-TNF alpha as [45] STRAND V，POPE J，TUNDIA N，et al. Upadacitinib
second-line drug therapy in patients with rheumatoid improves patient-reported outcomes in patients with rheu-
arthritis refractory to a first anti-TNF agent[J]. Reumatol matoid arthritis and inadequate response to conventional
Clin，2016，12（6）：319-322. synthetic disease-modifying antirheumatic drugs：results
[33] EMERY P，FURST D E，KIRCHNER P，et al. Risk of from SELECT-NEXT[J]. Arthritis Res Ther，2019，21（1）：
malignancies in patients with rheumatoid arthritis treated 272.
with rituximab：analyses of global postmarketing safety [46] HO LEE Y，GYU SONG G. Comparative efficacy and

·2812 · China Pharmacy 2021 Vol. 32 No. 22 中国药房 2021年第32卷第22期